The ASM sent a letter to Turing Pharmaceuticals regarding the company’s recent 5,000 percent cost increase for the decades old generic drug pyrimethamine (Daraprim).
The ASM sent a letter to Representatives Boustany and Thompson regarding their proposed Antibiotic and Rapid Diagnostic Research and Development Tax Credit Act of 2015. The legislation is designed to accelerate discovery of novel tools against drug resistant microbial pathogens.
The ASM submitted questions to the Administrator of the Centers for Medicare and Medicaid Services (CMS) on the implementation of Individualized Quality Control Plans (IQCPs) in the clinical microbiology laboratory. The answers sought will allow ASM to assist clinical microbiologists prepare for implementation of their own IQCPs by the deadline of January 2016.
The ASM submitted comments to the Centers for Disease Control and Prevention on the possession, use, and transfer of select agents and toxins. The comments addressed adding certain Influenza virus strains to the List of Select Agents and Toxins.
The ASM submitted comments to the National Institutes of Health (NIH) RFI on the Framework for the NIH-wide Strategic Plan. The comments will help NIH develop a 5-year strategic plan to outline a vision for biomedical research that will pursue fundamental knowledge about the nature and behavior of living systems and apply that knowledge to extend healthy life and reduce illness and disability.
August 17, 2015 - ASM Comments on Department of State and Commerce Control Regulations for Certain Pathogens
The ASM submitted comments to the US Department of Commerce and the US State Department regarding the Category XIV materials (Toxicological Agents, Including Chemical Agents, Biological Agents, and Associated Equipment) included on the United States Munitions List and the Commerce Control List.
The ASM presented recommendations to the Centers for Medicare & Medicaid Services at its annual public meeting on payment levels for new tests to be included in the 2016 Clinical Laboratory Fee Schedule.
January 28, 2015 - ASM Statement on the President’s Proposed 2016 Budget to Combat Antibiotic-Resistant Bacteria
The ASM released a statement on the President’s Proposed 2016 Budget to Combat Antibiotic-Resistant Bacteria.
The ASM sent comments on the 21st Centurey Cures Initiative to the House Committee on Energy and Commerce.
The ASM sent a letter to Senator Richard Durbin (D-IL) endorsing the bill which would provide a five percent increase in funding for biomedical research supported by the National Institutes of Health and other federal agencies involved in biomedical research.
April 21, 2015 - Energy & Environment Provisions in the America COMPETES Reauthorization Act of 2016
The ASM sent a letter to members of the House Committee on Science, Space and Technology about provisions in the America Competes Reauthorization Act of 2016, H.R. 1806.
The ASM submitted comments in response to the Office of Science and Technology and Policy's request for comment on the impact that the Select Agent Regulations have had on science, technology, and national security, and on the benefits, costs, and limitations of the regulations.
During the FDA Public Workshop “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” held on January 8-9, the ASM and the Pan American Society for Clinical Virology (PASCV) have commented on the implementation of this plan in clinical laboratories.
The ASM submitted comments to the Centers for Disease Control on the Biennial Review of the Select Agent Regulations.
The ASM sent a letter to members of Congress supporting passage of an FY 2015 Omnibus Appropriations bill to provide sustained and predictable federal funding for life science research and public health programs.
The ASM sent a letter to Sylvia Mathews Burwell, Secretary of Health and Human Services, Department of Health and Human Services regarding CDC Biosafety recommendations.
The ASM sent a letter to members of Congress supporting the Administration's $6.18 billion emergency funding request to combat the Ebola Virus outbreak.
The ASM submitted FY 2016 appropriations recommendations to the House and Senate Appropriations Committees.
October 28, 2014 - White House Office of Science and Technology Policy Challenge to Develop Ebola Tools
The ASM sent a message to members about a White House Office of Science and Technology Policy program that solicits the global community to share innovative ideas that deliver practical and cost-effective innovations to address this crisis, to improve delivery of care, and stem the spread of Ebola virus disease.